RecruitingAccepts healthy volunteersPhase 1
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Novo Nordisk A/S · NCT07767175
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–55 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1
- Target enrollment
- 142
- US sites recruiting
- 1
- Study start
- August 12, 2026
- Record last updated
- September 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Being studied: NNC0721-8060; Semaglutide; Placebo
Conditions: Overweight; Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male or female (sex at birth).
- Age 18-55 years (both inclusive) at the time of signing informed consent.
- Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
- Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Exclusion Criteria
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Previous randomisation in this study.
- History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
- Current participation (signed informed consent) in any other interventional clinical study.
- Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
- Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
- Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole [mmol/mol]) at screening.
Recruiting US locations
ICON Early Phase Services, LLC
Lenexa, KS 66219
Study contacts (from the official record)
- Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Similar studies in Kansas
All weight loss studies in Kansas →- RecruitingHealthy volunteersPhase 1
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
Novo Nordisk A/S
- Location
- Lenexa, KS
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Wichita, KS + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Wichita, KS + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Wichita, KS + 20 other US sites
- Eligibility basics
- Ages 18+